Furthermore, research into neutrophil markers like CD18 indicates that these markers are upregulated in neutrophils from OSCC tumors, particularly in metastatic cases, providing further evidence of their relevance to tumor progression [20]. This evidence concerns the gene ITGB2 and neoplasm.